Clinical and experimental dermatology · 2026
Laser-assisted vs. conventional daylight photodynamic therapies for actinic keratosis: a two-year randomized evaluator-blinded half-side comparative trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lindholm Vivian, Salmivuori Mari, Hahtola Sonja, Salava Alexander, Isoherranen Kirsi
Аннотация
BACKGROUND: Actinic field cancerization is considered a chronic and relapsing condition. Thus, long-term clearance and prevention of cutaneous squamous cell carcinoma should be the fundamental goal of treatment.
OBJECTIVES: This trial aims to compare long-term outcomes of two novel field treatments for actinic keratoses.
METHODS: The investigator-initiated intraindividual randomised controlled and evaluator-blinded trial compared fractional laser-assisted artificial- or natural daylight photodynamic therapy to daylight photodynamic therapy alone, as a split-head comparison of 60 patients with ≥ two actinic keratoses of the head, on a two-year follow-up.
RESULTS: The intention-to-treat analysis showed a significantly higher lesion-specific two-year sustained clearance with the laser-assisted treatment (p=0.003, 56.3% (147/261)) vs. 43.0% (108/251) for daylight photodynamic therapy alone. Additionally, 45.6% (26/57) of patients achieved two-year sustained partial clearance in the laser-assisted treatment compared to 31.6% (18/57) in daylight photodynamic therapy alone (p=0.064). Correspondingly, 15.8% (9/57) compared to 7.0% (4/57) of patients achieved sustained complete clearance (p=0.070). No squamous cell carcinomas developed on the treatment field, and in total three Bowen's diseases.
CONCLUSIONS: Laser-assisted daylight photodynamic therapy seems to achieve a higher long-term sustained clearance and may be superior also on long-term compared to daylight photodynamic therapy alone in the treatment of actinic keratosis of all grades.
OBJECTIVES: This trial aims to compare long-term outcomes of two novel field treatments for actinic keratoses.
METHODS: The investigator-initiated intraindividual randomised controlled and evaluator-blinded trial compared fractional laser-assisted artificial- or natural daylight photodynamic therapy to daylight photodynamic therapy alone, as a split-head comparison of 60 patients with ≥ two actinic keratoses of the head, on a two-year follow-up.
RESULTS: The intention-to-treat analysis showed a significantly higher lesion-specific two-year sustained clearance with the laser-assisted treatment (p=0.003, 56.3% (147/261)) vs. 43.0% (108/251) for daylight photodynamic therapy alone. Additionally, 45.6% (26/57) of patients achieved two-year sustained partial clearance in the laser-assisted treatment compared to 31.6% (18/57) in daylight photodynamic therapy alone (p=0.064). Correspondingly, 15.8% (9/57) compared to 7.0% (4/57) of patients achieved sustained complete clearance (p=0.070). No squamous cell carcinomas developed on the treatment field, and in total three Bowen's diseases.
CONCLUSIONS: Laser-assisted daylight photodynamic therapy seems to achieve a higher long-term sustained clearance and may be superior also on long-term compared to daylight photodynamic therapy alone in the treatment of actinic keratosis of all grades.